– Webcasted Q2-2025 conference call scheduled for August 26th at 5:00 PM EDT –

TORONTO and DALLAS, Aug. 11, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, today announced preliminary unaudited revenues for the second quarter ended June 30, 2025, senior management changes, and the creation of a Perimeter Industry Advisory Board ("IAB").

Preliminary Unaudited Second Quarter 2025 Revenues

Unless otherwise indicated, all amounts in this press release are expressed in U.S. dollars.

– Webcasted Q2-2025 conference call scheduled for August 26th at 5:00 PM EDT –

TORONTO and DALLAS, Aug. 11, 2025 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, today announced preliminary unaudited revenues for the second quarter ended June 30, 2025, senior management changes, and the creation of a Perimeter Industry Advisory Board ("IAB").

Preliminary Unaudited Second Quarter 2025 Revenues

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

TORONTO and DALLAS, July 29, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that it has closed the second tranche of its previously announced prospectus offering (the "Offering") of units of the Company (the "Units") and pre-funded units of the Company. The Offering was completed on a reasonable "best efforts" agency basis pursuant to an agency agreement (the "Agency Agreement") dated May 29, 2025 between the Company and A.G.P. Canada Investments ULC (the "Agent"). Pursuant to the Offering, the Company has issued an aggregate of 7,416,667 Units at a price of $0.30 per Unit for aggregate gross proceeds of approximately $2,225,000. Inclusive of the closing of the initial tranche, the Company has issued an aggregate of 17,849,468 Units pursuant to the Offering, for aggregate gross proceeds of approximately $5,354,840. The Company does not expect to close any further tranches of the Offering.

Deployment follows participation in pivotal trial of Perimeter's next-gen technology with AI for breast-conserving surgeries

TORONTO and DALLAS, July 2, 2025 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announced today that Medical City Dallas Hospital, an award-winning 899-bed acute care hospital in the Dallas-Fort Worth area, has adopted the company's current S-Series OCT (optical coherence tomography) technology for high-resolution visualization of tissue microstructures during surgery. The move comes on the heels of the hospital's participation in the pivotal, randomized controlled trial of Perimeter's next-generation B-Series device, which combines proprietary artificial intelligence ("AI") technology with OCT, and is being evaluated by the U.S. Food and Drug Administration for use during breast-conserving surgeries in the United States.

Deployment follows participation in pivotal trial of Perimeter's next-gen technology with AI for breast-conserving surgeries

TORONTO and DALLAS, July 2, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announced today that Medical City Dallas Hospital, an award-winning 899-bed acute care hospital in the Dallas-Fort Worth area, has adopted the company's current S-Series OCT (optical coherence tomography) technology for high-resolution visualization of tissue microstructures during surgery. The move comes on the heels of the hospital's participation in the pivotal, randomized controlled trial of Perimeter's next-generation B-Series device, which combines proprietary artificial intelligence ("AI") technology with OCT, and is being evaluated by the U.S. Food and Drug Administration for use during breast-conserving surgeries in the United States.

TORONTO and DALLAS, June 10, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that its CEO, Adrian Mendes, will present an update on the Company's business at the Life Sciences Virtual Investor Forum on Thursday, June 12, 2025 at 12:30 p.m. Eastern Time.

A live stream of the presentation will be available here and on the Investors section of Perimeter's website, where it will also be archived for approximately 90 days.

TORONTO and DALLAS, June 10, 2025 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that its CEO, Adrian Mendes, will present an update on the Company's business at the Life Sciences Virtual Investor Forum on Thursday, June 12, 2025 at 12:30 p.m. Eastern Time.

A live stream of the presentation will be available here and on the Investors section of Perimeter's website, where it will also be archived for approximately 90 days.

Registry aims to collect thousands of images and data from surgeries performed nationwide

TORONTO and DALLAS, June 4, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company") announced today that it has launched the OCT-Tissue Surveillance Registry, a database that aims to collect thousands of images and data from surgical procedures performed using the company's imaging technology. Perimeter will use the registry to inform future product development and continually enhance the artificial intelligence ("AI") deep-learning model for its investigational next-generation technology.

Registry aims to collect thousands of images and data from surgeries performed nationwide

TORONTO and DALLAS, June 4, 2025 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company") announced today that it has launched the OCT-Tissue Surveillance Registry, a database that aims to collect thousands of images and data from surgical procedures performed using the company's imaging technology. Perimeter will use the registry to inform future product development and continually enhance the artificial intelligence ("AI") deep-learning model for its investigational next-generation technology.

/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

TORONTO and DALLAS, June 3, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that it has completed its previously announced prospectus offering (the "Offering") of units of the Company (the "Units") and pre-funded units of the Company. The Offering was completed on a reasonable "best efforts" agency basis pursuant to an agency agreement (the "Agency Agreement") dated May 29, 2025 between the Company and A.G.P. Canada Investments ULC (the "Agent"). Pursuant to the Offering, the Company has issued an aggregate of 10,432,801 Units at a price of $0.30 per Unit (the "Offering Price") for aggregate gross proceeds of $3,129,840.

TORONTO and DALLAS, May 23, 2025 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that it has entered into a Development Support Agreement ("DSA") with Salt Lake City-based Intermountain Health, the largest nonprofit health system in the Intermountain West. This agreement creates the framework for the two organizations to partner on a number of future studies evaluating the potential value of using Perimeter's OCT and collecting additional data to support the continued development of the Company's artificial intelligence ("AI") algorithms.

TORONTO and DALLAS, May 23, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that it has entered into a Development Support Agreement ("DSA") with Salt Lake City-based Intermountain Health, the largest nonprofit health system in the Intermountain West. This agreement creates the framework for the two organizations to partner on a number of future studies evaluating the potential value of using Perimeter's OCT and collecting additional data to support the continued development of the Company's artificial intelligence ("AI") algorithms.

TORONTO and DALLAS, May 8, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSX-V: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announced it will report its first quarter 2025 financial and operating results after market close on Tuesday, May 13, 2025. Following the announcement, Perimeter management will host a webcast and conference call to discuss the results and provide a corporate update.

TORONTO and DALLAS, May 8, 2025 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSX-V: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announced it will report its first quarter 2025 financial and operating results after market close on Tuesday, May 13, 2025. Following the announcement, Perimeter management will host a webcast and conference call to discuss the results and provide a corporate update.

– First-ever successful pivotal trial of a new intraoperative margin assessment technology in breast cancer –

– Pivotal trial met its primary endpoint with statistically significant reduction in patients with residual cancer during surgery (p-value = 0.0050) and demonstrated super-superiority compared to standard-of-care alone–

– ASBrS presentation highlighted both these previously reported positive topline results and new additional analyses, including secondary endpoints and additional reporting –

– First-ever successful pivotal trial of a new intraoperative margin assessment technology in breast cancer –

– Pivotal trial met its primary endpoint with statistically significant reduction in patients with residual cancer during surgery (p-value = 0.0050) and demonstrated super-superiority compared to standard-of-care alone–

– ASBrS presentation highlighted both these previously reported positive topline results and new additional analyses, including secondary endpoints and additional reporting –

TORONTO and DALLAS, April 30, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company") announced today that HonorHealth, a leading healthcare system serving more than five million people in the greater Phoenix and Scottsdale areas, is the first in Arizona to deploy the Company's S- Series OCT (Optical Coherence Tomography) technology to visualize tissue margins in the operating room ("OR").

"Having the most advanced technologies in the operating room to assist my decision-making in real-time is incredibly valuable," said Dr. Sommer Gunia, a breast surgical oncologist with HonorHealth. "OCT imaging technology allows me to see at a depth and resolution that was previously impossible in the OR, and it has become an important tool that helps me achieve the best possible outcomes for my patients."

TORONTO and DALLAS, April 30, 2025 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company") announced today that HonorHealth, a leading healthcare system serving more than five million people in the greater Phoenix and Scottsdale areas, is the first in Arizona to deploy the Company's S- Series OCT (Optical Coherence Tomography) technology to visualize tissue margins in the operating room ("OR").

"Having the most advanced technologies in the operating room to assist my decision-making in real-time is incredibly valuable," said Dr. Sommer Gunia, a breast surgical oncologist with HonorHealth. "OCT imaging technology allows me to see at a depth and resolution that was previously impossible in the OR, and it has become an important tool that helps me achieve the best possible outcomes for my patients."

TORONTO and DALLAS, April 28, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that management will present an update on the Company's business at the 2025 Bloom Burton & Co. Healthcare Investor Conference on Monday, May 5, 2025 at 9:30 a.m. Eastern Time at the Metro Toronto Convention Centre.

The presentation will also be broadcast live and archived on the Company's website under "News/Events" in the Investors section.

TORONTO and DALLAS, April 28, 2025 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that management will present an update on the Company's business at the 2025 Bloom Burton & Co. Healthcare Investor Conference on Monday, May 5, 2025 at 9:30 a.m. Eastern Time at the Metro Toronto Convention Centre.

The presentation will also be broadcast live and archived on the Company's website under "News/Events" in the Investors section.